Strategic collaboration forms to develop brain cancer treatment
Biopharmaceutical company, Bioasis, and Hong-Kong based biologics company, WuXi Biologics, have announced an initial strategic collaboration for the development and manufacture of xB3-001 — a candidate for the treatment of brain cancer.
Under the terms of this collaboration, Bioasis will draw on the expertise of WuXi Biologics in developing complex biological molecules for production of xB3-001 (Bioasis’ lead investigational candidate) to ultimately support analytical development, formulation and IND-enabling in vivo studies. WuXi Biologics will focus on ensuring that Bioasis’ drug product candidates are manufactured with optimal formulation, stability and exceptional quality for the clinic.
“The initiation of manufacturing for xB3-001 is a pivotal milestone for Bioasis as we look to advance our lead program in HER2+ breast cancer brain metastases,” said Mark Day, PhD, president and chief executive officer, Bioasis. “WuXi Biologics’ expertise and experience in manufacturing biologics is instrumental to Bioasis in developing our pipeline.”
“We are excited to take on this work with Bioasis to enable them bringing innovative therapies to patients suffering from brain cancer,” said Dr Chris Chen, chief executive officer, WuXi Biologics. “This collaboration allows us to leverage our expertise across biological drug development and anticipate Bioasis’ needs as they move from pre-clinical to clinical and beyond.”